Botulinum Toxin in Movement Disorders: An Update
Since its initial approval in 1989 by the US Food and Drug Administration for the treatment of blepharospasm and other facial spasms, botulinum toxin (BoNT) has evolved into a therapeutic modality for a variety of neurological and non-neurological disorders. With respect to neurologic movement disor...
Kaydedildi:
| Asıl Yazarlar: | , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
MDPI AG
2021-01-01
|
| Seri Bilgileri: | Toxins |
| Konular: | |
| Online Erişim: | https://www.mdpi.com/2072-6651/13/1/42 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|